On December 15, 2025, Royal Philips announced it has entered into an agreement to acquire Massachusetts-based SpectraWAVE, an innovator in enhanced vascular imaging of coronary arteries, angiography-based physiology assessments, and the use of AI in medical imaging. Wilson Sonsini Goodrich & Rosati is advising SpectraWAVE on the transaction.

SpectraWAVE’s intravascular imaging and physiological assessment technologies provide advanced solutions for the treatment of patients with coronary artery disease, the most frequent type of heart disease, affecting more than 300 million people worldwide. The acquisition will expand Philips’ existing intravascular imaging and physiological assessment device portfolio. Financial terms of the agreement are not disclosed.

The Wilson Sonsini team that is advising SpectraWAVE on the transaction included:

Corporate
Jason Skolnik
Cassie Wetzel
Brandon Shaw
Michael Coury
Stephanie Chen

Technology Transactions
Jamie Clessuras

Regulatory
Eva Yin

Tax
Myra Sutanto Shen
Annie Jeong

Employee Benefits and Compensation
Brandon Gantus
Greg Hughes
Emma Wilcox

Employment
Matt Gorman
Alison Genova
Juliet Parker

Antitrust and Competition
Michelle Yost Hale
Kimberley Biagioli

National Security
Joshua Gruenspecht
Waqas Shahid

For more information, please see Philips' news release. Additional coverage can be found on Fierce Biotech and MassDevice.